Condition
Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma
Estimated Enrollment: 34
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: NCI-2009-00656|CDR0000539269|N0623|U10CA025224
Study First Received: April 11, 2007
Last Updated: January 28, 2015
Estimated Primary Completion Date: April 2009
Primary Outcome Measures:
Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)|Overall Survival|Progression-free Survival Assessed by RECIST|Determine the Clinical Toxicities of This Drug in This Participant Population.|Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.|Overall Response Rate
Sponsors and Collaborators:
National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00459862
